In the present study, significantly higher levels of FABP1, but not FABP4, were observed in RA patients with moderate-to-severe NAFLD than in those with none-to-mild NAFLD. This evidence concerns the gene FABP1 and metabolic dysfunction-associated steatotic liver disease.